We reported that using the full kallikrein panel would reduce biopsy rates by more than 50% for men with elevated PSA while missing only a small number of cancers (31 out of 152 low-grade and 3 out of 40 high-grade cancers). This evidence concerns the gene KLK3 and cancer.